PS-TURIN

(Turinabol Tablets USP 10 mg)

COMPOSITION:

Each tablet contains: Turinabol USP 10 mg

Read this entire leaflet carefully before you use this medicine Chlorodehydromethylandrostenediol (CDMA), also known as 4-chloro-17a-methylandrost-1,4-diene-3ẞ,17ẞ-diol, is a synthetic, orally active anabolic-androgenic steroid (AAS) and a 17a-alkylated derivative of 4-androstenediol that was never marketed.[1] It was first encountered in 2005 when it was introduced as a “dietary supplement” and putative prohormone under the name Halodrol-50 by industry veteran, Bruce Kneller while working with the dietary supplement company, Gaspari Nutrition.[1][2] The drug was the subject of a scathing and highly critical article by The Washington Post in November 2006. [1] CDMA was voluntarily discontinged by Gaspari Nutrition in mid-2006, likely fearing government sanctions if it continued to sell the product.[1] During the brief period of time that CDMA was sold online, it was an extremely well-selling product; its total sales are estimated to have been greater than twenty five million dollars, and by some estimates, CDMA may have been the best-selling hormonal product ever sold “over-the-counter” (ie., without a prescription) in the United States.[1]CDMA continued to be sold online until the 2014 prohormone ban as generic versions known as clones.

Disposition and excretion of the anabolic steroid Oral-Turinabol (1:4-chloro-17 alpha-methyl-androsta-1,4-diene-

17 beta-hydroxy-3-one) were investigated in male volunteers. Following single p.o. and i.v. administration of the

tritium-labelled compound the plasma concentration courses of total radioactivity (1 and 1-metabolites) and of the unchanged parent drug as well as the urinary excretion were estimated. From these data model independent pharmacokinetic parameters based on statistical moments were calculated. 1 is almost completely absorbed after p.o. administration of 10 mg per volunteer. Peak concentrations of total radioactivity and of 1 in plasma were reached about 3 h p.a. Irregularities observed in the plasma level profile following both p.o: and iv. administration of 1 are due to a marked enterohepatic circulation. Orally given 1 is subject to a first-pass effect, resulting in a diminished systematic availability. The AUC-ratio of the “unchanged drug and the total radioactivity of 1:13 shows the predominance of metabolites in plasma.

After 1.v. administration the disposition of unchanged I was found biphasically with a terminal half-life of 16 h, 1 and its

metabolites are preferentially excreted via the kidneys. The urinary total radioactivity represented about 60% of the dose following both administrations. Due to its affinity to SHBG 1 is able to compete for the protein binding of testosterone, resulting in an increased plasma level of non protein-bound testosterone